To Challenge Intellectual Property Appellate Board Verdict Rejecting Its Patent Plea For Cancer Drug
Nina Mehta MUMBAI
THE Indian subsidiary of Swiss drugmaker Novartis will challenge a decision by the Intellectual Property Appellate Board (IPAB) that said its cancer drug Glivec was not patentable.
Links:
[1] http://admin.indiaenvironmentportal.org.in/news/novartis-not-ready-give-glivec
[2] http://admin.indiaenvironmentportal.org.in/category/newspaper/economic-times-new-delhi
[3] http://admin.indiaenvironmentportal.org.in/category/thesaurus/cancer
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/health
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drug-industry
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/patents
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/intellectual-property-rights-ipr